Preventive strategies in chronic liver disease: part II. Cirrhosis
- PMID: 11759080
Preventive strategies in chronic liver disease: part II. Cirrhosis
Abstract
Cirrhosis is a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules. The modified Child-Pugh score, which ranks the severity of cirrhosis based on signs and liver function test results, has been shown to predict survival. Strategies have been established to prevent complications in patients with cirrhosis. Esophageal varices can be identified by endoscopy; if large varices are present, prophylactic nonselective beta blocker therapy should be administered. Alpha-fetoprotein testing and ultrasonography can be effective in screening for hepatocellular carcinoma. Vaccines should be administered to prevent secondary infections. The use of nonsteroidal anti-inflammatory drugs should be avoided, and patients should maintain a balanced diet containing 1 to 1.5 g of protein per kg per day. An extensive assessment should be performed before patients with cirrhosis undergo elective surgery. Before advanced liver decompensation occurs, patients should be referred for liver transplantation evaluation. If advanced cirrhosis is present and transplantation is not feasible, survival is between one and two years.
Similar articles
-
[Complications of liver cirrhosis: oesophageal varices, ascites and hepato-cellular carcinoma].Rev Med Suisse. 2005 Jan 19;1(3):249-50, 252-5. Rev Med Suisse. 2005. PMID: 15770820 Review. French.
-
Outpatient management of cirrhosis: a narrative review.South Med J. 2006 Jun;99(6):600-6. doi: 10.1097/01.smj.0000220889.36995.54. South Med J. 2006. PMID: 16800415 Review.
-
Complications of cirrhosis.Dis Mon. 2008 Jul;54(7):445-56. doi: 10.1016/j.disamonth.2008.03.006. Dis Mon. 2008. PMID: 18570914 Review. No abstract available.
-
[Management of non-complicated cirrhosis].Rev Prat. 1997 Mar 1;47(5):507-12. Rev Prat. 1997. PMID: 9138413 French.
-
[Cirrhosis and complications].Rev Prat. 2001 Dec 15;51(20):2271-9. Rev Prat. 2001. PMID: 11828645 French. No abstract available.
Cited by
-
Therapeutic effects and molecular mechanisms of anti-fibrosis herbs and selenium on rats with hepatic fibrosis.World J Gastroenterol. 2004 Mar 1;10(5):703-6. doi: 10.3748/wjg.v10.i5.703. World J Gastroenterol. 2004. PMID: 14991942 Free PMC article.
-
Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.World J Gastroenterol. 2002 Aug;8(4):679-85. doi: 10.3748/wjg.v8.i4.679. World J Gastroenterol. 2002. PMID: 12174378 Free PMC article. Clinical Trial.
-
Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease.Dig Dis Sci. 2006 Jan;51(1):41-4. doi: 10.1007/s10620-006-3082-6. Dig Dis Sci. 2006. PMID: 16416209
-
Inhibitory effect of Huangqi Zhechong decoction on liver fibrosis in rat.World J Gastroenterol. 2004 Aug 1;10(15):2295-8. doi: 10.3748/wjg.v10.i15.2295. World J Gastroenterol. 2004. PMID: 15259087 Free PMC article.
-
Protective effect of selenium-enriched Lactobacillus on CCl4-induced liver injury in mice and its possible mechanisms.World J Gastroenterol. 2005 Oct 7;11(37):5795-800. doi: 10.3748/wjg.v11.i37.5795. World J Gastroenterol. 2005. PMID: 16270387 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical